@stockrock
Reading between the lines is the very reason why in the MSB forum, we regularly witness some of the most heated discussions on HC. This problem is not really helped by MSB management's tendency to talk up its achievements and quietly ignore its setbacks. And sometimes they are simply quite clumsy in explaining simple things, which then created all of these contradictory interpretations.
As an example, reading MSB announcement on 11/01/2016 about CHF trial size being reduced from 1165 to 600, one gets the impression that this was a good development and that MSB, Teva and FDA have an open line of communication about this trial and things are progressing well.
And yet, less than 5 months later, we were given a trading halt surprise which was then followed with the announcement of Teva's withdrawal.
Another example is the announcement of Kentgrove's Equity Financing Facility. Shareholders were reassured by Silviu himself that this will not be dilutive, that he will do the right thing by the shareholders. This however contradicts the very definition of an equity financing which involved the issuance of shares in return for cash.
Although this facility so far has not been used, since then MSB however had raised capital twice, first to MNK, followed by another private placement. Both of which involved dilution against existing loyal shareholders.
Instead of reading between the lines like yourself, I prefer to follow Rod Tidwell's advice (the character in the movie Jerry Maguire).
SHOW! ME! THE! MONEY!
FDA or FBI or CIA can give MSB any kind of designations they want, RMAT, RAT, CAT, BAT, but if MSB runs out of money beforehand, these will amount to nothing!
In other words, partnership dollars please, nothing less!
(20min delay)